Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned an average recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $421.2820.

ALNY has been the subject of several recent research reports. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Evercore ISI lifted their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an “overweight” rating in a report on Wednesday, August 6th. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Finally, Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a report on Friday, August 1st.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,979 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $3,163,371.33. Following the completion of the transaction, the chief executive officer directly owned 56,221 shares in the company, valued at approximately $25,483,292.67. The trade was a 11.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the transaction, the director owned 775 shares of the company’s stock, valued at $362,390. This represents a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock valued at $33,968,256 in the last three months. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ALNY. Norges Bank bought a new position in Alnylam Pharmaceuticals in the second quarter worth about $662,837,000. Holocene Advisors LP bought a new position in Alnylam Pharmaceuticals in the second quarter worth about $194,616,000. Orbis Allan Gray Ltd raised its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares in the last quarter. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new position in Alnylam Pharmaceuticals in the first quarter worth about $69,292,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.2%

NASDAQ:ALNY opened at $468.58 on Friday. Alnylam Pharmaceuticals has a twelve month low of $205.87 and a twelve month high of $484.21. The company has a market cap of $61.42 billion, a price-to-earnings ratio of -189.71 and a beta of 0.32. The stock has a fifty day simple moving average of $398.78 and a 200-day simple moving average of $315.32. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period last year, the company earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.